- Home
- FPF vs SYRE Comparison
FPF vs SYRE Comparison
Compare FPF & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPF
- SYRE
- Stock Information
- Founded
- FPF 2013
- SYRE 2013
- Country
- FPF United States
- SYRE United States
- Employees
- FPF N/A
- SYRE N/A
- Industry
- FPF Trusts Except Educational Religious and Charitable
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- FPF Finance
- SYRE Health Care
- Exchange
- FPF Nasdaq
- SYRE Nasdaq
- Market Cap
- FPF 1.1B
- SYRE 1.2B
- IPO Year
- FPF N/A
- SYRE 2016
- Fundamental
- Price
- FPF $18.33
- SYRE $19.49
- Analyst Decision
- FPF
- SYRE Strong Buy
- Analyst Count
- FPF 0
- SYRE 8
- Target Price
- FPF N/A
- SYRE $51.50
- AVG Volume (30 Days)
- FPF 186.7K
- SYRE 681.3K
- Earning Date
- FPF 01-01-0001
- SYRE 02-27-2025
- Dividend Yield
- FPF 8.08%
- SYRE N/A
- EPS Growth
- FPF N/A
- SYRE N/A
- EPS
- FPF N/A
- SYRE N/A
- Revenue
- FPF N/A
- SYRE N/A
- Revenue This Year
- FPF N/A
- SYRE N/A
- Revenue Next Year
- FPF N/A
- SYRE N/A
- P/E Ratio
- FPF N/A
- SYRE N/A
- Revenue Growth
- FPF N/A
- SYRE N/A
- 52 Week Low
- FPF $13.91
- SYRE $17.24
- 52 Week High
- FPF $18.09
- SYRE $47.97
- Technical
- Relative Strength Index (RSI)
- FPF 32.39
- SYRE 42.77
- Support Level
- FPF $18.72
- SYRE $17.24
- Resistance Level
- FPF $18.84
- SYRE $20.00
- Average True Range (ATR)
- FPF 0.15
- SYRE 1.74
- MACD
- FPF -0.06
- SYRE -0.08
- Stochastic Oscillator
- FPF 3.66
- SYRE 35.38
About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.